SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, say Mayo Clinic researchers who presented results of several clinical trials at the 53rd annual meeting of the American Society of Hematology, Dec. 10-13, in San Diego.
